Active surveillance is a management strategy for low-risk prostate cancer where, instead of immediate surgery or radiation therapy, the tumor is closely monitored using PSA tests, MRI scans, and scheduled biopsies1. Its goal is to avoid the side effects of treatment for tumors that are unlikely to progress, without missing the window for curative treatment if they do change1,2. It is definitely not the same as doing nothing.
Who is active surveillance for?
European Association of Urology (EAU) guidelines recommend it for low-risk tumors and select favorable intermediate-risk cases1. Generally, it is considered when:
- The biopsy shows a low-grade tumor (ISUP grade group 1, equivalent to Gleason 3 + 3).
- PSA levels and physical exam indicate disease confined entirely to the prostate.
- The MRI does not show evidence of a more extensive tumor.
- You, fully informed about the alternatives, prefer to postpone treatment and commit to attending your follow-up visits.
Many low-grade prostate cancers grow very slowly over years, and the risk of overtreating them is one of the main reasons this strategy exists2,3. The decision also takes into account your age, overall health, and personal preferences.
How is prostate cancer monitored?
Follow-up combines several tests at intervals determined by your urologist's protocol1,3:
| Test | Purpose |
|---|---|
| Periodic PSA | To detect changes in PSA levels and its rate of rise |
| Physical exam | To identify changes in the consistency or size of the prostate |
| MRI scan | To monitor the size and appearance of suspicious areas |
| Confirmatory and surveillance biopsies | To ensure the tumor grade has not increased |
Sticking to the schedule is a critical part of the strategy: active surveillance works because it allows any changes in the tumor to be detected early1.
Active surveillance vs. watchful waiting: what is the difference?
Both terms sound similar, but clinical guidelines distinguish clearly between them1:
| Feature | Active Surveillance | Watchful Waiting |
|---|---|---|
| Goal | Treat with curative intent if the tumor progresses | Manage symptoms if they appear, without aiming for a cure |
| Who it's for | Men who would be candidates for surgery or radiation | Men with significant coexisting health conditions or limited life expectancy |
| Follow-up | Scheduled PSA, MRI, and biopsies | Symptom-driven, with fewer routine tests |
| If changes occur | Prostatectomy or radiation therapy is offered | Palliative treatments, such as hormone therapy, are offered |
When do you transition to treatment?
Active treatment is recommended when monitoring reveals the tumor is more significant than initially thought1:
- A follow-up biopsy shows a higher grade (for example, shifting from ISUP group 1 to group 2 or higher).
- The number of positive biopsy cores or tumor volume increases.
- The MRI shows tumor growth or a new suspicious lesion.
An isolated change in PSA usually prompts further testing rather than immediate treatment1. You can also transition to treatment if, at any point, you prefer to stop active surveillance. Curative options include radical prostatectomy and radiation therapy1.
Frequently asked questions
Is it safe not to treat prostate cancer right away?
In well-selected low-risk tumors, clinical guidelines consider active surveillance a safe, appropriate option, provided that follow-up is strictly maintained1,2. Its major advantage is avoiding or delaying the side effects of surgery or radiation, such as urinary incontinence or erectile dysfunction. The key requirement is commitment: scheduled studies ensure curative treatment can still be delivered if the tumor changes.
Can I change my mind and choose treatment later?
Yes. Active surveillance does not close the door to active treatment: if studies show progression or if you decide at any time that you would prefer to be treated, curative options such as radical prostatectomy or radiation therapy will be discussed1. This decision can be revisited at every follow-up visit with your urologist, weighing clear information on benefits and risks.
Dr. Manuel Alejandro González Ramírez, specialist in Urology, Endourology, and Robotic Surgery at CURO, Centro Urológico de Occidente, explains in consultation whether active surveillance is an option for your case. Read the complete guide on prostate cancer: symptoms and diagnosis or learn about care for prostate cancer in Guadalajara.
References
- Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2026 Update. Part I: Screening, Diagnosis, and Local Treatment With Curative Intent. European Urology. 1 de septiembre de 2026.
- Raychaudhuri, Lin, Montgomery. Prostate Cancer: A Review. JAMA. 22 de abril de 2025.
- Williams, McVey, Perera, et al. Modern Paradigms for Prostate Cancer Detection and Management. The Medical Journal of Australia. 17 de octubre de 2022.
